pSivida gets Austrian approval for eye drug; IntelGenx starts trials for migraine film;

 @DamianFierce: Tamarisk plans to "turn the industry upside down" with oral insulin platform. News | Follow @DamianFierce

> pSivida ($PSDV) has received marketing authorization in Austria for Iluvien, a treatment for vision impairment using the company's back-of-the-eye delivery platform. The approval is a step toward EMA approval, the company said. Release

> IntelGenx has launched trials for VersaFilm, its anti-migraine oral film, in Canada. The goal is to establish safety and bioequivalency for a future FDA application. More

> PCI Biotech has partnered with Modulight to develop a medical laser system to trigger endosomal drug release into cancerous cells. Report

> An Army researcher has discovered a new way to carry vaccines that could have drug delivery implications. Article